Moreover, a recent study suggests that pharmacologic inhibition of type‐I PRMTs also perturbs RNA splicing globally and synergizes with PRMT5 inhibition to induce antitumor effects.129 Based on these observations, it would be tempting to speculate that leukemias bearing spliceosome gene mutations may also confer differential sensitivity to PRMT5 and/or type‐I PRMT inhibitors. Here, PRMT5 is linked to leukemia.